May 15, 2017
Mereo BioPharma wraps up patients testing for its rare pulmonary disease drug
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has completed patient enrolment in the AETHER, multi-centre, double-blind, placebo-controlled Phase 2 dose-ranging study of acumapimod (BCT-197), for the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).